5174-90-3

Basic information

• Product Name: 2-OXO-1,2-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 2-OXO-1,2-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER;Ethyl 2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate;1,2-Dihydro-3-(ethoxycarbonyl)-2-oxo-1,8-naphthyridine;Ethyl 1,2-dihydro-2-oxo-1,8-naphthyridine-3-carboxylate 95+%
• CAS NO: 5174-90-3
• Molecular Formula: C₁₁H₁₀N₂O₃
• Molecular Weight: 218.21
• Mol File: 5174-90-3.mol
• Article Data: 26

Chemical Properties

• Melting Point: 214.8-215.0°C
• Boiling Point: 452.9°Cat760mmHg
• Flash Point: 227.7°C
• Appearance: /
• Density: 1.303g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-OXO-1,2-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-OXO-1,2-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER(5174-90-3)
• EPA Substance Registry System: 2-OXO-1,2-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER(5174-90-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 5174-90-3(Hazardous Substances Data)

Usage

General Description

2-OXO-1,2-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER is a chemical compound with a complex structure consisting of a naphthyridine ring and a carboxylic acid ethyl ester group. It is commonly used in pharmaceutical research and drug development as a potential candidate for new drug discovery. 2-OXO-1,2-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER has been studied for its potential pharmacological properties, including its anti-inflammatory and anti-cancer effects. Its unique structure and diverse biological activities make it a promising target for further investigation and potential therapeutic applications in the future.

InChI:InChI=1/C11H10N2O3/c1-2-16-11(15)8-6-7-4-3-5-12-9(7)13-10(8)14/h3-6H,2H2,1H3,(H,12,13,14)

Upstream product

• 7521-41-7 2-Aminonicotinaldehyde 
• 105-53-3 diethyl malonate 
• 1071-46-1 hydrogen ethyl malonate 
• 2033-24-1 cycl-isopropylidene malonate 
• 64-17-5 ethanol 
• 7521-27-9 2-(3-pyridyl)-1,3,8-triazanaphthalene 
• 98-92-0 nicotinamide 
• 86847-59-8 2-(pivaloylamino)pyridine 
• 86847-64-5 N-(3-formyl-2-pyridinyl)-2,2-dimethylpropanamide 

Downstream Products

• 1160012-33-8 N-(4-fluorophenethyl)-1,8-naphthyridin-2(1H)-on-3-carboxamide 
• 1160012-25-8 N-cyclohexyl-1,8-naphthyridin-2(1H)-on-3-carboxamide 
• 1160012-31-6 N-phenethyl-1,8-naphthyridin-2(1H)-on-3-carboxamide 
• 1160012-27-0 N-(4-methylcyclohexyl)-1,8-naphthyridin-2(1H)-on-3-carboxamide 
• 1239164-04-5 3-(2-hydroxy-6-oxo-1-cyclohexenecarbonyl)-1-methyl-1,8-naphthyridin-2(1H)-one 
• 1239164-56-7 3-oxo-1-cyclohexenyl 1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-carboxylate 
• 1239164-12-5 1-benzyl-3-(2-hydroxy-6-oxo-1-cyclohexenecarbonyl)-1,8-naphthyridin-2(1H)-one 
• 1239164-60-3 3-oxo-1-cyclohexenyl 1-benzyl-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate 
• 132209-79-1 ethyl 2-chloro-1,8-naphthyridine-3-carboxylate 

Relevant articles and documents

Ferric Chloride-catalyzed Synthesis of 2-Oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate Derivatives and Their Biological Evaluation

A new methodology has been developed for the synthesis of novel 2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylates from 2-aminonicotinaldehyde, Meldrum’s acid, and the corresponding alcohols in the presence of anhydrous iron(III) chloride as a cheap and readily available catalyst. The structure of the synthesized compounds was established by IR, 1H NMR, and mass spectral data and elemental analyses. All the synthesized compounds were evaluated for their in vitro antibacterial and antifungal activity, and the activity of some derivatives was comparable with the activity of Ciprofloxacin and Nystatin used as reference drugs.

Development of [18f]lu14 for pet imaging of cannabinoid receptor type 2 in the brain

Cannabinoid receptors type 2 (CB2R) represent an attractive therapeutic target for neurodegenerative diseases and cancer. Aiming at the development of a positron emission tomography (PET) radiotracer to monitor receptor density and/or occupancy during a CB2R-tailored therapy, we herein describe the radiosynthesis of cis-[18F]1-(4-fluorobutyl-N-((1s,4s)-4-methylcyclohexyl)-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide ([18F]LU14) starting from the corresponding mesylate precursor. The first biological evaluation revealed that [18F]LU14 is a highly affine CB2R radioligand with >80% intact tracer in the brain at 30 min p.i. Its further evaluation by PET in a well-established rat model of CB2R overexpression demonstrated its ability to selectively image the CB2R in the brain and its potential as a tracer to further investigate disease-related changes in CB2R expression.

5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.